Takeda Pharmaceutical Co. Ltd reported on December 6, 2025, that new data from their Phase 3 VERIFY study showed 61.9% of patients treated with rusfertide maintained a durable response in managing polycythemia vera over 52 weeks, indicating its potential effectiveness. The findings highlight significant improvements in hematocrit control and a substantial reduction in the need for phlebotomy.